erlotinib hydrochloride has been researched along with diosgenin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (diosgenin) | Trials (diosgenin) | Recent Studies (post-2010) (diosgenin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,095 | 6 | 723 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, H; Lou, W; Wang, J; Wu, T; Zhu, KY | 1 |
1 other study(ies) available for erlotinib hydrochloride and diosgenin
| Article | Year |
|---|---|
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diosgenin; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Lung Neoplasms; Melanthiaceae; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Rhizome; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |